GLUE Stock Up 45% on Positive Interim Data on Inflammation Drug

Monte Rosa Therapeutics GLUE jumped 45.41% following positive interim data from a phase-I study evaluating its immunology and inflammation pipeline candidate, MRT-8102. The candidate is a NEK7-directed molecular glue degrader (“MGD”), being developed for the treatment of inflammatory conditions driven by NLRP3, IL-1, and IL-6.

The phase I MRT-8102 study is a randomized, double-blind, placebo-controlled study in healthy volunteers and higher cardiovascular-risk subjects, designed to assess safety, tolerability, pharmacokinetics, and pharmacodynamic effects, including NEK7 degradation and reductions in inflammatory markers such as C-reactive protein (“CRP”).

Over the past year, GLUE’s shares have surged 288.7% compared with the industry’s 20.5% rise.

Key Points of Interim Study Results

Interim results demonstrated robust and consistent activity of MRT-8102 across all study cohorts. A total of 48 patients were enrolled in the single-dose cohorts, 40 patients in the multiple-dose cohorts, and 24 patients with higher cardiovascular-risk completed four weeks of treatment in part 3.

MRT-8102 achieved approximately 80–90% NEK7 degradation across all dose levels.

High-sensitivity CRP (hsCRP) level, a key inflammation marker, was reduced by 85% in the higher-risk group of patients after four weeks of dosing versus placebo, with nearly all patients reaching low-risk levels.

Treatment with MRT-8102 also lowered endogenous IL-6 below the cardiovascular risk threshold and strongly suppressed IL-1β secretion in patients with elevated CRP levels at baseline. In a small number of patients, the drug significantly reduced cerebrospinal fluid IL-6 levels, suggesting possible central nervous system activity.

The drug was well-tolerated and showed a favorable safety profile.

Monte Rosa’s Other Development Activities for 2026

Monte Rosa plans to report complete data from the GFORCE-1 study of MRT-8102 in patients with elevated cardiovascular risk in the first half of 2026, followed by the initiation of the phase II GFORCE-2 study in patients with atherosclerotic cardiovascular disease later in the year.

The company also expects partner Novartis to initiate multiple mid-stage studies of MRT-6160 in immune-related diseases in 2026.

Monte Rosa plans to present updated data from the ongoing phase I/II study of MRT-2359 at the ASCO Genitourinary Cancers Symposium in February 2026 and to initiate the MODeFIRe-1 phase II study of MRT-2359 in patients with solid tumors, including CRPC, later in the year.

Additionally, the company intends to submit IND applications in 2026 to the regulatory authority for next-generation NEK7-directed MGD and a CDK2 and/or cyclin E1-directed MGD, further expanding its inflammation and oncology pipeline.

Monte Rosa Therapeutics’ Zacks Rank & Other Stocks to Consider

GLUE currently carries a Zacks Rank #2 (Buy).

Some other top-ranked stocks in the biotech sector are Amicus Therapeutics FOLD, CorMedix CRMD, and Indivior INDV, each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Over the past 60 days, estimates for Amicus Therapeutics’ 2026 earnings per share have declined from 67 cents to 65 cents. Shares of FOLD have increased 51.1% over the past year.

Amicus Therapeutics’ earnings beat estimates in one quarter and missed in the remaining three trailing quarters with the negative average surprise being 20.21%.

Over the past 60 days, 2026 EPS estimates for CorMedix have risen from $2.49 to $2.88. Shares of CRMD have risen 3.3% over the past year.

CorMedix’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 27.04%.

Over the past 60 days, estimates for Indivior’s 2026 earnings per share have risen to $2.85 from $2.60. Indivior stock has rallied 196.8% over the past year.

Indivior’s earnings beat estimates in three of the trailing four quarters and were in line in the remaining quarter, with the average surprise being 68%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research